Posted by ABMN Staff on May 13th, 2024
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) – B. Riley reduced their Q2 2024 earnings estimates for Madrigal Pharmaceuticals in a note issued to investors on Thursday, May 9th. B. Riley analyst M. Mamtani...
More of this article »